The Limited Times

Now you can see non-English news...

For Servier, a new life begins


In order to turn the page on the Mediator, the second French laboratory is betting above all on oncology.

One new medicine or one new indication per year.

This is the challenge that Servier is setting itself between now and 2030. The second French laboratory intends to change dimensions by this horizon.

It plans to reach 8 billion euros in turnover (compared to 4.7 billion in 2021), i.e. a growth of nearly 60%, and to increase its profitability, by targeting an Ebitda of more than 30% .

Thirteen years after the Mediator affair, which again weighed down the accounts of its last financial year, Servier therefore definitely intends to turn the page by projecting itself into the future.

“This is a new chapter in our history,

confides Olivier Laureau, president of Servier since 2014, who has just presented his new roadmap.

After a first stage of our transformation launched in 2017, we are accelerating this dynamic.”

To achieve this, he is betting above all on oncology, the largest market in the pharmaceutical industry, which will have to generate 40% of activity (compared to 12% last year).

An objective…

This article is for subscribers only.

You have 78% left to discover.

Cultivating your freedom is cultivating your curiosity.

Keep reading your article for €0.99 for the first month


Already subscribed?


Source: lefigaro

All business articles on 2022-10-05

You may like

Business 2022-10-05T20:14:17.131Z

Trends 24h

Business 2022-11-27T20:45:11.316Z


© Communities 2019 - Privacy